Protagonist Therapeutics (PTGX) announced the submission of a new drug application to the FDA by Johnson & Johnson (JNJ) seeking the first approval of icotrokinra. Icotrokinra is designed to block the IL-23 receptor, which underpins the inflammatory response in plaque PsO and offers potential in other IL-23-mediated diseases. Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist announces NDA submission by Johnson & Johnson for icotrokinra
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Protagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
- Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
- Protagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities